ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
'Patients are left not knowing': Trastuzumab (Herceptin) cardiac risk information and management in HER2-positive breast cancer-a qualitative study of patient experience.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe current study investigated the extent of knowledge and care regimen regarding the possible risks of cardiac dysfunction from Trastuzumab (Herceptin) treatment in women with either a diagnosis of primary or metastatic breast cancer who had undergone or were receiving Trastuzumab at the time of the study.
methodIn a qualitative interview, participants were asked questions regarding awareness of cardiac risks of Trastuzumab therapy and knowledge of cardiac damage symptoms, as well as questions concerning the regimen of heart function monitoring during and beyond their course of treatment. Thematic analysis was used to analyse the data.
resultsThe emerging themes from the thematic analysis revealed inconsistencies in (a) knowledge and awareness of cardiac damage risk prior to taking Trastuzumab, (b) monitoring of cardiac function and risks of cardiac dysfunction during and beyond treatment, and (c) awareness of signs of possible cardiac damage of Trastuzumab during treatment.
conclusionsOur results suggest that patients feel unsupported and ill-informed about the possible risks of cardiac damage from Trastuzumab. This has implications for the self-management of symptoms and mitigation of risks for cardiac damage and suggests the need for improvement in patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.